66 related articles for article (PubMed ID: 23000651)
1. Efficacy of allogeneic and autologous hematopoietic SCT in patients with AML after first complete remission.
Jing Y; Li H; Zhao Y; Bo J; Wang S; Wang Q; Huang W; Gao C; Yu L
Bone Marrow Transplant; 2013 Mar; 48(3):383-9. PubMed ID: 23000651
[TBL] [Abstract][Full Text] [Related]
2. Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.
Saraceni F; Labopin M; Gorin NC; Blaise D; Tabrizi R; Volin L; Cornelissen J; Cahn JY; Chevallier P; Craddock C; Wu D; Huynh A; Arcese W; Mohty M; Nagler A;
J Hematol Oncol; 2016 Sep; 9(1):79. PubMed ID: 27589849
[TBL] [Abstract][Full Text] [Related]
3. Comparison of allo-SCT, auto-SCT and chemotherapy for the treatment of patients with low- or intermediate-risk acute myeloid leukemia: a network meta-analysis.
Ye W; Wu X; Zhao R; Jin X; Li H; Qu Y; Ji J; Liu Z
Stem Cell Res Ther; 2024 May; 15(1):153. PubMed ID: 38816870
[TBL] [Abstract][Full Text] [Related]
4. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes.
Yu S; Lin T; Nie D; Zhang Y; Sun Z; Zhang Q; Wang C; Xiong M; Fan Z; Huang F; Xu N; Liu H; Yu G; Zhang H; Shi P; Xu J; Xuan L; Guo Z; Wu M; Han L; Xiong Y; Sun J; Wang Y; Liu Q
Blood Cancer J; 2021 Dec; 11(12):195. PubMed ID: 34873148
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective analysis of prognosis in favorable-risk acute myeloid leukemia patients with different consolidation regimens].
Wang HY; Bao XB; Tang XW; Sun AN; Wu DP; Zhou HX; Qiu HY
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):517-522. PubMed ID: 28655096
[No Abstract] [Full Text] [Related]
6. [Efficacy of Activated Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia].
Ren RR; Ma LM; Wang T; Xie YX; Zhu QJ; Gao ZL; Tian WW; Gong R; Niu YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(5):1509-1515. PubMed ID: 37846709
[TBL] [Abstract][Full Text] [Related]
7. Comparison of autologous, matched sibling, and alternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study.
Wang M; Zhang H; Zheng X; Liu J; Wang J; Cao Y; Zhang X; Zhang R; Chen X; Zhai W; Ma Q; Wei J; Huang Y; Yang D; He Y; Pang A; Feng S; Han M; Jiang E
Hematol Oncol; 2024 Jan; 42(1):e3230. PubMed ID: 37752767
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Positive t(8;21) Acute Myeloid Leukemia.
Wang X; Xu X; Zhang H; Zhou W; Gong D; Zhu C; Zhou D; Chen G
Ann Transplant; 2023 Dec; 28():e942197. PubMed ID: 38111188
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Autologous Hematopoietic Stem Cell Transplantation versus Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation for Follicular Lymphoma: Systematic Review and Meta-Analysis.
Liu X; Zheng Y; Li H; Wang M; You MJ; Tian C
Oncology; 2023; 101(12):822-835. PubMed ID: 37598665
[TBL] [Abstract][Full Text] [Related]
10. Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
Wei M; Xie C; Huang J; Liu Q; Lai Y
Hematology; 2023 Dec; 28(1):2269509. PubMed ID: 37850613
[TBL] [Abstract][Full Text] [Related]
11. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy.
Fløisand Y; Remberger M; Bigalke I; Josefsen D; Vålerhaugen H; Inderberg EM; Olaussen RW; Gjertsen BT; Goedkoop R; Geiger C; Prinz PU; Schnorfeil FM; Pinkernell K; Schendel DJ; Kvalheim G
Leukemia; 2023 Sep; 37(9):1842-1849. PubMed ID: 37507426
[TBL] [Abstract][Full Text] [Related]
12. A Comparison of the Physical Activity and Sedentary Behavior between Autologous and Allogeneic Hematopoietic Stem Cell Transplantation Survivors.
Nakagami T; Tawara Y; Arizono S; Shinya J; Naito K
Intern Med; 2023 Sep; 62(18):2643-2650. PubMed ID: 36725046
[TBL] [Abstract][Full Text] [Related]
13. Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Baron F; Efficace F; Cannella L; Stevens-Kroef M; Amadori S; de Witte T; Lübbert M; Venditti A; Suciu S
Am J Hematol; 2024 Mar; 99(3):486-489. PubMed ID: 38174977
[TBL] [Abstract][Full Text] [Related]
14. Auto-hematopoietic stem cell transplantation or chemotherapy? Meta-analysis of clinical choice for AML.
Ge S; Wang J; He Q; Zhu J; Liu P; Wang H; Zhang F
Ann Hematol; 2024 Jan; ():. PubMed ID: 38267560
[TBL] [Abstract][Full Text] [Related]
15. HSCT prolongs remission of high-risk CTCLs.
Killock D
Nat Rev Clin Oncol; 2023 Jul; 20(7):426. PubMed ID: 37147418
[No Abstract] [Full Text] [Related]
16. Monocytes in allo-HSCT with aged donors secrete IL-1/IL-6/TNF to increase the risk of GVHD and damage the aged HSCs.
Li X; Zhang W; Wang Y; Li C; Wu Y; Shang Y; Lin H; Li Y; Wang Y; Zeng X; Cen Z; Lai X; Luo Y; Qian P; Huang H
iScience; 2024 Mar; 27(3):109126. PubMed ID: 38405615
[TBL] [Abstract][Full Text] [Related]
17. The Role of Outpatient Physical Medicine and Rehabilitation in a Multidisciplinary Prehabilitation Program for Older Adults before Allogeneic Hematopoietic Stem Cell Transplant.
Cheng JT; Obaisi O; Yadav R; Gupta E; Fu JB; Bruera E; Collaco A; Szewcyzk N; Popat U; Ngo-Huang A
Am J Phys Med Rehabil; 2024 Jan; ():. PubMed ID: 38207179
[TBL] [Abstract][Full Text] [Related]
18. Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study.
Guo W; Cao Y; Liu J; Zheng X; Wang M; Zheng Y; Zhang X; Zhai W; Chen X; Zhang R; Ma Q; Yang D; Wei J; He Y; Pang A; Feng S; Han M; Jiang E
Bone Marrow Transplant; 2023 Oct; 58(10):1163-1166. PubMed ID: 37474728
[No Abstract] [Full Text] [Related]
19. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).
Küley-Bagheri Y; Kreuzer KA; Monsef I; Lübbert M; Skoetz N
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD011960. PubMed ID: 30080246
[TBL] [Abstract][Full Text] [Related]
20. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
Liu H; Zhai X; Song Z; Sun J; Xiao Y; Nie D; Zhang Y; Huang F; Zhou H; Fan Z; Tu S; Li Y; Guo X; Yu G; Liu Q
J Hematol Oncol; 2013 Feb; 6():15. PubMed ID: 23394705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
